GenoMed Applies for Listing on American Stock Exchange
Tuesday July 6, 9:30 am ET

ST. LOUIS, July 6 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED - News), a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it has applied to be listed on the American Stock Exchange.
ADVERTISEMENT


The Company expects to hear from the Exchange in 6-8 weeks about the status of its application.

Dr. David Moskowitz, CEO and Chief Medical Officer of GenoMed, remarked, "This is a major step in continuing the momentum we have recently established. Moving from the Pink Sheets will increase investor confidence, improve liquidity, and most importantly, allow for increased institutional investment.

Many large investors are not permitted to buy Pink Sheets securities."

About GenoMed

GenoMed is a Next Generation DM(TM) [Disease Management] company which uses knowledge of disease-causing genes to improve patient outcomes. The Company's goal this summer is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" link at http://www.genomedics.com .

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether we are listed by the American Stock Exchange; (b) whether our treatment for West Nile virus encephalitis is effective for larger numbers of patients; (c) whether our server holds up to heavy demand; (d) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

--------------------------------------------------------------------------------
Source: GenoMed, Inc.

GMED - GENOMED INC (OTC)
Date Open High Low Last Change Volume % Change
07/06/04 0.1600 0.1900 0.1500 0.1850 +0.0250 2147890 +15.63%

Composite Indicator
Trend Spotter (TM) Sell

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Buy

Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 629260

Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Sell
20 - 100 Day MACD Oscillator Sell
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 25% - Sell
50-Day Average Volume - 1106508

Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 1556455

Overall Average: 24% - Buy

Price Support Pivot Point Resistance

0.1850 0.1350 0.1750 0.2150

NEWS**** Finance Rearrangement

GENOMED SECURES ACCELERATED FINANCING

CONTACT: GenoMed Inc.
David W. Moskowitz, MD, MA, FACP
314/652-0500
dwmoskowitz@genomedics.com

For Immediate Release

ST. LOUIS, MO. – July 15, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve patient outcomes, today announced that it has secured up to $21 million in financing within a 12-month period from Pierpoint Investissements SA ("Pierpoint"), a Swiss-based venture capital group.

GenoMed and Pierpoint have amended their earlier agreement dated March 2, 2004. In the earlier agreement, Pierpoint could exercise 35 million warrants over a 5 year period once GenoMed's share price reached $1. Under the new agreement, Pierpoint can exercise all 35 million warrants within a 12-month period. The exercise of all 35 million warrants at a 40% discount to market price would bring at least $21 million into the company.

As an incentive to place all 35 million warrants within a year, Pierpoint would receive 80 million replacement warrants. If Pierpoint can place only 20 million warrants within a year, they would receive 40 million replacement warrants. These can then be exercised over a minimum of 5 years, as in the earlier agreement.

Dr. David Moskowitz, GenoMed's Chairman and CEO, said, "We are delighted to have secured a mechanism for accelerated funding. This will allow our genotyping effort to expand as fast as scientifically feasible. Within the next few years, we hope to corner the market on disease-predisposition genes.”

Dr. Moskowitz is a Harvard and Oxford trained physician, and is a noted pioneer in the field of medical genomics. He has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes, emphysema, and psoriasis.

About GenoMed